Clinical trials in Lisbon – page 54

648 clinical trials in Lisbon, Portugal across 3 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Lisbon at a glance

648

clinical trials

Research sites3

Quick filters

648 trials in Lisbon

Open in trial search

Cystic fibrosis

Not recruiting

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo

Long-term safety and efficacy study of elexacaftor/tezacaftor/ivacaftor treatment in people with cystic fibrosis who have non-F508del genetic mutations

Registered drugNo placebo

Portugal

Participants:0–17 years · 18–64 years
Substances:Elexacaftor
Sponsor:Vertex Pharmaceuticals Inc.

Contact Research Centre

Frontotemporal dementia

Not recruiting

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational

Study on the Effects of Latozinemab for Patients with Frontotemporal Dementia Due to Progranulin Gene Mutations

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Latozinemab
Sponsor:Alector LLC

Contact Research Centre

Hormone-refractory prostate cancer+1

Not recruiting

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Study on Talazoparib and Enzalutamide for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Enzalutamide
Sponsor:Pfizer Inc.

Contact Research Centre

Multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug

Study on the Effectiveness and Safety of Frexalimab and Teriflunomide in Adults with Relapsing Multiple Sclerosis

Registered drug

Portugal

Participants:18–64 years
Substances:Colestyramine
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo

Study of Retifanlimab, INCAGN02385, and INCAGN02390 for First-Line Treatment in Patients with PD-L1 Positive Recurrent/Metastatic Head and Neck Cancer

InvestigationalNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Retifanlimab
Sponsor:Incyte Biosciences International S.a.r.l.

Contact Research Centre

Systemic lupus erythematosus

Not recruiting

Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational

Study on the Effectiveness and Safety of Cenerimod for Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:Cenerimod
Sponsor:Viatris Innovation GmbH

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo

Study on the Safety and Effectiveness of Volrustomig with a Drug Combination for Patients with Solid Tumors

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:AstraZeneca AB

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

Registered drugNo placebo

Study comparing enfortumab vedotin versus chemotherapy combination (docetaxel, paclitaxel, vinflunine) in patients with previously treated advanced or metastatic bladder cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:Astellas Pharma Global Development Inc.

Contact Research Centre

Mantle cell lymphoma stage II+2

Not recruiting

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo

Study on Ibrutinib and Drug Combination for Patients with Generalized Mantle Cell Lymphoma

Registered drugNo placebo

Portugal

Participants:18–64 years
Substances:Ibrutinib
Sponsor:Klinikum der Universitaet Muenchen AöR

Contact Research Centre

Primary amyloidosis

Not recruiting

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug

Study on Birtamimab and Bortezomib for Patients with Advanced Light Chain Amyloidosis

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Birtamimab
Sponsor:Prothena Biosciences Limited

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy

Investigational

Study of RO7790121 Treatment for Adults with Moderate to Severe Ulcerative Colitis: Testing Effectiveness and Safety in Initial and Long-term Therapy

Investigational

Portugal

Participants:18–64 years · 65+ years
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Colitis ulcerative

Not recruiting

Study of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis

Investigational

Study of RO7790121 Compared to Placebo for Treatment of Adults with Moderate to Severe Ulcerative Colitis

Investigational

Portugal

Participants:18–64 years · 65+ years
Substances:RO7790121
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 48 cities in Portugal

Clinical research in Lisbon

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on head and neck cancer treatments and advanced lung cancer therapies, combining novel approaches with standard treatments.

Head & Neck Squamous Cell Carcinoma
Mantle Cell Lymphoma
Non-small Cell Lung Cancer

Studies evaluate targeted therapies and immunotherapy combinations to improve patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, with particular focus on psoriasis and systemic sclerosis treatments.

Psoriatic Arthritis
Sjögren's Syndrome
Plaque Psoriasis

Testing innovative biological therapies and novel treatment approaches.

03 Neurological Disorders

Studies examining treatments for Dravet Syndrome and Alzheimer's-related psychosis, focusing on improving patient quality of life.

Alzheimer's Disease Psychosis
Epilepsy Conditions

Investigating new therapeutic options for challenging neurological conditions.

04 Inflammatory Diseases

Research targeting Crohn's Disease and various inflammatory conditions, evaluating new treatment combinations.

Pyoderma Gangrenosum
Chronic Rhinosinusitis
Hidradenitis Suppurativa

Testing advanced therapies for chronic inflammatory conditions.

Back to Portugal All countries